Details for New Drug Application (NDA): 021231
✉ Email this page to a colleague
NDA 021231 describes ZOMIG-ZMT, which is a drug marketed by Astrazeneca and is included in one NDA. Additional details are available on the ZOMIG-ZMT profile page.
The generic ingredient in ZOMIG-ZMT is zolmitriptan. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.
The generic ingredient in ZOMIG-ZMT is zolmitriptan. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.
Summary for 021231
| Tradename: | ZOMIG-ZMT |
| Applicant: | Astrazeneca |
| Ingredient: | zolmitriptan |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Feb 13, 2001 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Sep 17, 2001 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
